Arkolith/Insider Trading/URGN/Form 4

Smith Jason Drew

General CounselUroGen Pharma Ltd. (URGN) · full profile →Form 4 · filed Feb 4, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$82K
Net Open-Market Flow
-$82K
Transactions
10
6 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 31, 2025Sell(S)3K$11.14$31K33K
Jan 31, 2025Option exercise(M)7K——33K
Jan 31, 2025Option exercise(M)3K——28K
Jan 31, 2025Sell(S)1K$11.14$14K26K
Jan 31, 2025Sell(S)3K$11.14$37K30K
Jan 31, 2025Option exercise(M)6K——35K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 31, 2025Option exercise(M)6K—$011K
Jan 31, 2025Option exercise(M)7K—$07K
Jan 31, 2025Option exercise(M)3K—$00
Jan 31, 2025Grant(A)10K—$010K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-25-002685) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML